In a patient with recurrent colorectal cancer, what role does microsatellite instability (MSI) testing play in guiding treatment decisions?

MSI Testing is Critical in Recurrent Colorectal Cancer

Yes, MSI testing plays an essential role in recurrent colorectal cancer and should be performed to determine eligibility for immune checkpoint inhibitor therapy, which can dramatically improve outcomes in MSI-high tumors. 1

Primary Treatment Indication: Immunotherapy Eligibility

MSI/dMMR status is a powerful predictive biomarker for PD-1/PD-L1 checkpoint inhibitors in metastatic/recurrent colorectal cancer. Patients with MSI-high tumors demonstrate remarkable responses to immunotherapy, fundamentally changing the treatment landscape 2. This has become standard of care based on phase III trials showing superior efficacy of checkpoint inhibitors in this population 3.

Key Clinical Actions:

• Test all patients with advanced/recurrent colorectal cancer for MSI/MMR status before or during standard treatment 1
• MSI-high status makes patients eligible for first-line anti-PD-1 monotherapy or anti-PD-1 + anti-CTLA-4 combination therapy 3
• Testing turnaround is 1-2 weeks, so initiate early to avoid treatment delays 1

Testing Methodology

Immunohistochemistry (IHC) for MMR proteins (MLH1, MSH2, MSH6, PMS2) is the highly recommended first-line test 2. This approach has:

• Strong consensus support (100% agreement among experts) 1
• High concordance with PCR-based methods (96.6% consistency) 4
• Practical advantages in most pathology laboratories

Alternative/complementary methods:

• PCR-based microsatellite testing (using ≥5 markers including BAT-25 and BAT-26) when IHC is equivocal or unavailable 2
• NGS panels that can simultaneously assess MSI and tumor mutational burden, particularly useful for comprehensive molecular profiling 2

Prognostic and Predictive Implications Beyond Immunotherapy

MSI status provides additional clinical value:

Prognostic information:

• MSI-high tumors generally have better stage-adjusted survival in early-stage disease 5
• In metastatic disease, MSI-high may confer worse prognosis with conventional chemotherapy 5

Chemotherapy resistance:

• MSI-high tumors show potential resistance to 5-fluorouracil-based chemotherapy 1, 5
• This influences treatment sequencing decisions—immunotherapy should be prioritized over traditional chemotherapy in MSI-high recurrent disease

Critical Pitfalls to Avoid

1. Don't delay testing: With 1-2 week turnaround, late testing may force suboptimal treatment choices or delay optimal therapy 1

2. Confirm MSI-high status if early progression occurs on immunotherapy: 10-30% of patients show primary resistance, and pseudo-progression must be distinguished from true progression 3

3. Consider Lynch syndrome screening: Approximately 3% of MSI-high colorectal cancers are hereditary (Lynch syndrome), requiring genetic counseling and germline testing 6

4. Don't assume all MSI-high tumors respond equally: BRAF V600E mutations may influence outcomes and require special consideration 3

Treatment Algorithm for Recurrent CRC

1. Obtain MSI/MMR testing immediately upon diagnosis of recurrence
2. If MSI-high/dMMR: Consider checkpoint inhibitor therapy as first-line treatment (anti-PD-1 ± anti-CTLA-4) 3
3. If MSS/pMMR: Proceed with conventional chemotherapy regimens; immunotherapy generally ineffective 7
4. Monitor for response: MSI-high tumors may show delayed responses; assess carefully for pseudo-progression 3

The evidence strongly supports that MSI testing is not optional but essential in recurrent colorectal cancer, as it identifies a subset of patients (approximately 15% of CRCs) who may achieve dramatic, durable responses to immunotherapy that would otherwise receive ineffective chemotherapy 8, 5.